Vaidya Sane Ayurved Laboratories Ltd (MADHAVBAUG) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1003610,
    "name": "Vaidya Sane",
    "stock_name": "Vaidya Sane",
    "full_name": "Vaidya Sane Ayurved Laboratories Ltd",
    "name_url": "stocks-analysis/vaidya-sane",
    "exchange": 1,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "275.00",
    "chg": "0.00",
    "chgp": "0.00%",
    "dir": 0,
    "prev_price": "275.00",
    "mcapval": "289.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "MADHAVBAUG",
    "ind_name": "Hospital",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE0JR301013",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": 1600,
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/vaidya-sane-1003610-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Vaidya Sane Sees Revision in Market Evaluation Amid Mixed Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/vaidya-sane-upgraded-from-sell-to-hold-by-marketsmojo-on-3-june-2025-3743969",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/VaidyaSane_mojoScore_3743969.png",
        "date": "2025-12-03 11:08:25",
        "description": "Vaidya Sane, a microcap player in the hospital sector, has experienced a revision in its market evaluation reflecting nuanced shifts across key analytical parameters. This adjustment comes amid a backdrop of strong year-to-date returns and a complex financial and technical profile, prompting investors to reassess the stock’s positioning within its sector."
      },
      {
        "title": "Is Vaidya Sane overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-vaidya-sane-overvalued-or-undervalued-3678258",
        "imagepath": "",
        "date": "2025-11-07 08:14:34",
        "description": "As of 6 November 2025, the valuation grade for Vaidya Sane has moved from expensive to very expensive. The company is currently considered overvalued. Key ratios include a PE ratio of 48.20, an EV to EBITDA of 26.00, and a PEG ratio of 0.11, which indicates a significant premium compared to its peers.\n\nIn comparison to its industry peers, Sun Pharma has a PE ratio of 35.02 and an EV to EBITDA of 10.54, while Cipla is valued more attractively with a PE ratio of 22.27 and an EV to EBITDA of 5.53. Despite Vaidya Sane's strong year-to-date return of 90.47%, which outperforms the Sensex's 7.89%, the current valuation metrics suggest that the stock is not justified at its price level...."
      },
      {
        "title": "How has been the historical performance of Vaidya Sane?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-vaidya-sane-3677372",
        "imagepath": "",
        "date": "2025-11-06 23:04:18",
        "description": "Answer:\nThe historical performance of Vaidya Sane shows a significant growth trajectory, particularly from fiscal year Mar'22 to Mar'25.\n\nBreakdown:\nVaidya Sane's net sales increased from zero in Mar'22 to 89.85 Cr in Mar'25, although there was a decline from 99.33 Cr in Mar'24. Total operating income followed a similar trend, rising from zero to 89.85 Cr, with a slight decrease from the previous year. The company managed to reduce its total expenditure from 94.83 Cr in Mar'24 to 76.34 Cr in Mar'25, contributing to an operating profit (PBDIT) of 15.37 Cr in Mar'25, up from 6.25 Cr in Mar'24. Profit before tax also saw a notable increase, reaching 9.90 Cr in Mar'25 compared to 2.86 Cr in Mar'24, while profit after tax rose to 7.15 Cr from 1.99 Cr. The earnings per share (EPS) improved significantly from 1.88 in Mar'24 to 6.79 in Mar'25. On the balance sheet, total liabilities increased from 54.81 Cr in Mar'2..."
      },
      {
        "title": "Why is Vaidya Sane falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-vaidya-sane-fallingrising-3657008",
        "imagepath": "",
        "date": "2025-10-29 23:36:13",
        "description": "As of 29-Oct, Vaidya Sane Ayurved Laboratories Ltd is experiencing a price increase, currently at 274.95, reflecting a rise of 2.95 or 1.08%. The stock has shown strong performance today, outperforming its sector by 0.34%. Additionally, it has higher moving averages compared to the 5-day, 20-day, 100-day, and 200-day averages, although it is lower than the 50-day moving average. Notably, there has been a significant increase in investor participation, with delivery volume rising by 61.76% against the 5-day average. The stock has also demonstrated impressive returns over various periods, including a year-to-date increase of 98.45% and a one-year increase of 94.52%, indicating strong overall performance despite a slight decline of 1.80% over the past month.\n\nIn the broader market context, Vaidya Sane's short-term return of +6.98% over the past week significantly outpaces the benchmark Sensex, which has only i..."
      },
      {
        "title": "Vaidya Sane Ayurved Laboratories Ltd Surges 3.85% Today, Up 94.88% Year-to-Date",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/vaidya-sane-ayurved-laboratories-ltd-surges-385-today-up-9488-year-to-date-3643834",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/VaidyaSaneAyurv_only_buyers_3643834.png",
        "date": "2025-10-24 11:41:14",
        "description": "Vaidya Sane Ayurved Laboratories Ltd is experiencing notable buying interest, with a significant rise in its stock price today. Over the past week, month, and year, the company has outperformed the Sensex, reflecting strong momentum and positive sentiment in the microcap hospital sector."
      },
      {
        "title": "Vaidya Sane Ayurved Laboratories Stock Hits Upper Circuit at Rs 273.0, Up 5%",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/vaidya-sane-ayurved-laboratories-stock-hits-upper-circuit-at-rs-2730-up-5-3643755",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/VaidyaSaneAyurv_stocks_hitting_upper_circuit_3643755.png",
        "date": "2025-10-24 11:00:16",
        "description": "Vaidya Sane Ayurved Laboratories Ltd, a microcap in the hospital sector, saw significant trading activity today, reaching its upper circuit limit. The stock outperformed its sector and the Sensex, with notable trading volume and turnover. Despite a drop in delivery volume, liquidity remains adequate, indicating positive market sentiment."
      },
      {
        "title": "Why is Vaidya Sane falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-vaidya-sane-fallingrising-3624375",
        "imagepath": "",
        "date": "2025-10-15 23:54:10",
        "description": "As of 15-Oct, Vaidya Sane Ayurved Laboratories Ltd is experiencing a decline in its stock price, currently at 259.10, which reflects a decrease of 10.9 points or 4.04%. The stock has underperformed its sector by 4.12% today, and while it is higher than the 100-day and 200-day moving averages, it is lower than the 5-day, 20-day, and 50-day moving averages. Over the past week, the stock has seen a return of -9.63%, contrasting with the Sensex's gain of +1.11%. Despite this short-term decline, the stock has shown strong long-term performance, with an impressive year-to-date return of +87.01% and a one-year return of +85.14%. The company also demonstrates a strong ability to service its debt, indicated by a low Debt to EBITDA ratio of 0.38 times, and has achieved healthy operating profit growth at an annual rate of 47.54%.\n\nIn the broader market context, the stock's recent performance is notably weaker compared..."
      },
      {
        "title": "Is Vaidya Sane overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-vaidya-sane-overvalued-or-undervalued-3613699",
        "imagepath": "",
        "date": "2025-10-13 08:13:28",
        "description": "As of 10 October 2025, the valuation grade for Vaidya Sane has moved from very expensive to expensive. The company is currently considered overvalued based on its high valuation ratios. The PE ratio stands at 49.32, while the EV to EBITDA ratio is 26.37, and the PEG ratio is notably low at 0.11, indicating that the stock may not be justified at its current price level.\n\nWhen compared to peers, Vaidya Sane's valuation appears excessive, particularly against Sun Pharma's PE of 34.96 and EV to EBITDA of 23.7, and Cipla's more attractive ratios of 23.39 and 16.48, respectively. Additionally, despite a strong year-to-date stock return of 94.88%, the recent performance has lagged behind the Sensex, which returned 6.94% in the same period. This combination of high valuation ratios and peer comparisons suggests that Vaidya Sane is overvalued in the current market context...."
      },
      {
        "title": "Is Vaidya Sane overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-vaidya-sane-overvalued-or-undervalued-3612585",
        "imagepath": "",
        "date": "2025-10-12 08:12:02",
        "description": "As of 10 October 2025, the valuation grade for Vaidya Sane has moved from very expensive to expensive, indicating a slight improvement in its valuation perception. The company is currently considered overvalued. Key ratios include a PE ratio of 49.32, an EV to EBITDA of 26.37, and a PEG ratio of 0.11, which suggests that despite high earnings multiples, the growth prospects may not justify such valuations.\n\nIn comparison to its peers, Vaidya Sane's PE ratio significantly exceeds that of Sun Pharma, which stands at 34.96, and Cipla, which is at 23.39. This indicates that Vaidya Sane is priced at a premium relative to its industry peers, further supporting the overvaluation assessment. Additionally, while Vaidya Sane has shown impressive year-to-date returns of 94.88% compared to the Sensex's 6.94%, this performance does not mitigate the concerns regarding its current high valuation metrics...."
      }
    ],
    "total": 4815,
    "sid": "1003610",
    "stock_news_url": "https://www.marketsmojo.com/news/vaidya-sane-ayurved-laboratories-1003610"
  },
  "announcements": "",
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Vaidya Sane Ayurved Laboratories Ltd has declared <strong>2%</strong> dividend, ex-date: 05 Sep 23",
          "dt": "2023-09-05",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Vaidya Sane Sees Revision in Market Evaluation Amid Mixed Financial Signals

2025-12-03 11:08:25

Vaidya Sane, a microcap player in the hospital sector, has experienced a revision in its market evaluation reflecting nuanced shifts across key analytical parameters. This adjustment comes amid a backdrop of strong year-to-date returns and a complex financial and technical profile, prompting investors to reassess the stock’s positioning within its sector.

Is Vaidya Sane overvalued or undervalued?

2025-11-07 08:14:34

As of 6 November 2025, the valuation grade for Vaidya Sane has moved from expensive to very expensive. The company is currently considered overvalued. Key ratios include a PE ratio of 48.20, an EV to EBITDA of 26.00, and a PEG ratio of 0.11, which indicates a significant premium compared to its peers. In comparison to its industry peers, Sun Pharma has a PE ratio of 35.02 and an EV to EBITDA of 10.54, while Cipla is valued more attractively with a PE ratio of 22.27 and an EV to EBITDA of 5.53. Despite Vaidya Sane's strong year-to-date return of 90.47%, which outperforms the Sensex's 7.89%, the current valuation metrics suggest that the stock is not justified at its price level....

How has been the historical performance of Vaidya Sane?

2025-11-06 23:04:18

Answer: The historical performance of Vaidya Sane shows a significant growth trajectory, particularly from fiscal year Mar'22 to Mar'25. Breakdown: Vaidya Sane's net sales increased from zero in Mar'22 to 89.85 Cr in Mar'25, although there was a decline from 99.33 Cr in Mar'24. Total operating income followed a similar trend, rising from zero to 89.85 Cr, with a slight decrease from the previous year. The company managed to reduce its total expenditure from 94.83 Cr in Mar'24 to 76.34 Cr in Mar'25, contributing to an operating profit (PBDIT) of 15.37 Cr in Mar'25, up from 6.25 Cr in Mar'24. Profit before tax also saw a notable increase, reaching 9.90 Cr in Mar'25 compared to 2.86 Cr in Mar'24, while profit after tax rose to 7.15 Cr from 1.99 Cr. The earnings per share (EPS) improved significantly from 1.88 in Mar'24 to 6.79 in Mar'25. On the balance sheet, total liabilities increased from 54.81 Cr in Mar'2...

Why is Vaidya Sane falling/rising?

2025-10-29 23:36:13

As of 29-Oct, Vaidya Sane Ayurved Laboratories Ltd is experiencing a price increase, currently at 274.95, reflecting a rise of 2.95 or 1.08%. The stock has shown strong performance today, outperforming its sector by 0.34%. Additionally, it has higher moving averages compared to the 5-day, 20-day, 100-day, and 200-day averages, although it is lower than the 50-day moving average. Notably, there has been a significant increase in investor participation, with delivery volume rising by 61.76% against the 5-day average. The stock has also demonstrated impressive returns over various periods, including a year-to-date increase of 98.45% and a one-year increase of 94.52%, indicating strong overall performance despite a slight decline of 1.80% over the past month. In the broader market context, Vaidya Sane's short-term return of +6.98% over the past week significantly outpaces the benchmark Sensex, which has only i...

Vaidya Sane Ayurved Laboratories Ltd Surges 3.85% Today, Up 94.88% Year-to-Date

2025-10-24 11:41:14

Vaidya Sane Ayurved Laboratories Ltd is experiencing notable buying interest, with a significant rise in its stock price today. Over the past week, month, and year, the company has outperformed the Sensex, reflecting strong momentum and positive sentiment in the microcap hospital sector.

Vaidya Sane Ayurved Laboratories Stock Hits Upper Circuit at Rs 273.0, Up 5%

2025-10-24 11:00:16

Vaidya Sane Ayurved Laboratories Ltd, a microcap in the hospital sector, saw significant trading activity today, reaching its upper circuit limit. The stock outperformed its sector and the Sensex, with notable trading volume and turnover. Despite a drop in delivery volume, liquidity remains adequate, indicating positive market sentiment.

Why is Vaidya Sane falling/rising?

2025-10-15 23:54:10

As of 15-Oct, Vaidya Sane Ayurved Laboratories Ltd is experiencing a decline in its stock price, currently at 259.10, which reflects a decrease of 10.9 points or 4.04%. The stock has underperformed its sector by 4.12% today, and while it is higher than the 100-day and 200-day moving averages, it is lower than the 5-day, 20-day, and 50-day moving averages. Over the past week, the stock has seen a return of -9.63%, contrasting with the Sensex's gain of +1.11%. Despite this short-term decline, the stock has shown strong long-term performance, with an impressive year-to-date return of +87.01% and a one-year return of +85.14%. The company also demonstrates a strong ability to service its debt, indicated by a low Debt to EBITDA ratio of 0.38 times, and has achieved healthy operating profit growth at an annual rate of 47.54%. In the broader market context, the stock's recent performance is notably weaker compared...

Is Vaidya Sane overvalued or undervalued?

2025-10-13 08:13:28

As of 10 October 2025, the valuation grade for Vaidya Sane has moved from very expensive to expensive. The company is currently considered overvalued based on its high valuation ratios. The PE ratio stands at 49.32, while the EV to EBITDA ratio is 26.37, and the PEG ratio is notably low at 0.11, indicating that the stock may not be justified at its current price level. When compared to peers, Vaidya Sane's valuation appears excessive, particularly against Sun Pharma's PE of 34.96 and EV to EBITDA of 23.7, and Cipla's more attractive ratios of 23.39 and 16.48, respectively. Additionally, despite a strong year-to-date stock return of 94.88%, the recent performance has lagged behind the Sensex, which returned 6.94% in the same period. This combination of high valuation ratios and peer comparisons suggests that Vaidya Sane is overvalued in the current market context....

Is Vaidya Sane overvalued or undervalued?

2025-10-12 08:12:02

As of 10 October 2025, the valuation grade for Vaidya Sane has moved from very expensive to expensive, indicating a slight improvement in its valuation perception. The company is currently considered overvalued. Key ratios include a PE ratio of 49.32, an EV to EBITDA of 26.37, and a PEG ratio of 0.11, which suggests that despite high earnings multiples, the growth prospects may not justify such valuations. In comparison to its peers, Vaidya Sane's PE ratio significantly exceeds that of Sun Pharma, which stands at 34.96, and Cipla, which is at 23.39. This indicates that Vaidya Sane is priced at a premium relative to its industry peers, further supporting the overvaluation assessment. Additionally, while Vaidya Sane has shown impressive year-to-date returns of 94.88% compared to the Sensex's 6.94%, this performance does not mitigate the concerns regarding its current high valuation metrics....

View All News